Combining Transfer of TTF-1 and Pax-8 Gene: a Potential Strategy to Promote Radioiodine Therapy of Thyroid Carcinoma by Da Mu et al.
 1
Combining Transfer of TTF-1 and Pax-8 Gene: a Potential Strategy to Promote 
Radioiodine Therapy of Thyroid Carcinoma 
 
Da Mu1,2, Rui Huang1, Xiaojuan Ma1, Suping Li1, Anren Kuang1 
 
1Department of Nuclear Medicine, National Key Discipline of Medical Imaging and Nuclear 
medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China; 
2Department of Nuclear Medicine, Sir Run Run Shaw Hospital, School of Medicine, 
Zhejiang University, Hangzhou, China 
 
Correspondence author: 
 Professor Anren Kuang 
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 
Sichuan Province, China 610041      
E-mail:kuanganren@263.net 
Tel.:+86-028-85422696 
Fax: +86 28 85582944 
 
Running Title: Radioiodine therapy of tumor following TTF-1 and Pax-8 gene 
cotransfer 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
54
6.
1 
: P
os
te
d 
20
 O
ct
 2
01
1
 2
Abstract Cotransfer of TTF-1 and Pax-8 gene to tumor cells, resulting in the reexpression of 
iodide metabolism-associated proteins, such as sodium iodide symporter (NIS), 
thyroglobulin (Tg), thyroperoxidase (TPO), offers the possibility of radioiodine therapy to 
non-iodide-concentrating tumor because the expression of iodide metabolism-associated 
proteins in thyroid are mediated by the thyroid transcription factor TTF-1 and Pax-8. The 
human TTF-1 and Pax-8 gene were transducted into the human thyroid carcinoma (K1 and 
F133) cells by the recombinant adenovirus, AdTTF-1 and AdPax-8. Reexpression of NIS 
mRNA and protein, but not TPO and Tg mRNA and protein, was detected in 
AdTTF-1-infected F133 cells, following with increasing radioiodine uptake (6.1~7.4 times), 
scarcely iodide organification and rapid iodide efflux (t1/2≈8 min in vitro, t1/2≈4.7 h in vivo). 
On contrast, all of the reexpression of NIS, TPO and Tg mRNA and proteins in F133 cells 
were induced by the synergetic effect of TTF-1 and Pax-8. AdTTF-1 and AdPax-8 
coinfected K1 and F133 cells could effectively accumulate radioiodine (6.6~7.5 times) and 
obviously retarded radioiodine retention (t1/2≈25~30 min in vitro, t1/2≈12 h in vivo) (p<0.05). 
Accordingly, the effect of radioiodine therapy of TTF-1 and Pax-8 cotransducted K1 and 
F133 cells (21~25% survival rate in vitro) was better than that of TTF-1-transducted cells 
(40% survival rate in vitro) (p<0.05). These results indicate that single TTF-1 gene transfer 
may have limited efficacy of radioiodine therapy because of rapid radioiodine efflux. The 
cotransduction of TTF-1 and Pax-8 gene, with resulting NIS-mediated radioiodine 
accumulation and TPO and Tg-mediated radioiodine organification and intracellular 
retention, may lead to effective radioiodine therapy of thyroid carcinoma.  
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Introduction 
 
Radioiodide therapy is an effective approach for treatment of differentiated thyroid 
carcinoma and their metastases. Radioiodide therapy is based on the capacity of thyroid 
carcinoma cells to trap and concentrate iodide, which is completed by the cooperation of 
thyroid-specific proteins, such as the sodium/iodide symporter (NIS), thyroglobulin (Tg) and 
thyroperoxidase (TPO).1 However, to anaplastic thyroid carcinoma and any other nonthyroid 
carcinoma, which shows no radioiodine accumulation, radioiodide therapy is not suitable to 
them. It confines the extensive application of radioiodide therapy in clinic. NIS mediated 
iodide uptake in normal and well differentiated neoplastic thyroid cells. TPO catalyzes 
oxidation of iodide ion, iodination of tyrosine residues of Tg and coupling of iodotyrosines 
to generate iodothyronines T3 and T4 and, thus promotes iodide retention within thyroid 
cells. It is postulated that reexpression of these iodide metabolic proteins would enable 
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non-iodide-concentration tumor to acquire/restore the capacity of radioiodine concentration, 
which make it possible to treat non-iodide-concentration tumor with radioiodine.  
Transcription factors play a pivotal role in the determination and maintenance of 
cellular phenotype. The activity of transcription factors is considered as the main switch to 
regulate gene expression.2 The expression of those thyroid-specific proteins is controlled by 
the combination of specific transcription factors with the respective promoters/enhancers of 
those genes. In thyroid follicular cells, three thyroid-specific transcription factors (TTF) have 
been identified: TTF-1, TTF-2, and Pax-8, which regulate the transcriptional activity of Tg 
and other thyroid-specific genes, such as thyroperoxidase (TPO) and thyrotropin receptor 
(TSHr).3 TTF-1 is a homeodomain-containing protein expressed in embryonic diencephalons, 
thyroid, and lung.4 Pax-8 belongs to the Pax family of paired domain-containing genes and is 
expressed in the kidney, the developing excretory system, and the thyroid.5 Three TTF-1 
binding sites are present in the Tg and the TPO promoter. TTF-1 could activate transcription 
from the Tg promoter and, at a much low extent, from TPO promoter in both thyroid and 
nonthyroid cells.6 Pax-8 binds to a single site on the Tg and on the TPO promoters and, in 
both case, the Pax-8-binding site overlaps with that of TTF-1.7 In addition, TTF-1 could 
activated the rat NIS promoter by a direct interaction with its enhancer region8 and, Pax-8 
has two binding sites of rat NIS upstream enhancer and plays an important role in the 
expression of NIS gene.9 In addition to their expression in the follicular thyroid cells, TTF-1 
and Pax8 also expressed in the lung and kidney，respectively. However, the two factors are 
present together only in the thyroid follicular cell, suggesting that their combination could 
have a role in the expression of the thyroid-specific phenotype.10 
Ros and his colleages11 reported that TTF-1 and Pax8 were expressed in well 
differentiated thyroid adenomas and that their expression decreased in less differentiated 
papillary and follicular carcinomas and was lost in undifferentiated anaplastic carcinomas. 
They also affirmed that the expression of the thyroid specific genes Tg, TPO and TSHr and 
their transcription factors, TTF-1 and Pax8, was lost in thyroid cells derived from follicular 
papillary and anaplastic human carcinomas. Fabbro et al.10 found that, in anaplastic thyroid 
carcinomas, the absence of TTF-1 was associated with the absence of Tg gene expression. 
Both transcription factors directly interact and synergistically activate thyroid-specific 
transcription.6,12 TTF-1 and Pax-8 cooperate with several ubiquitous transcription factors, 
forming complexes on the regulatory region of specific genes.13,14 Miccadel et al. reported 
that TTF-1 and Pax-8 cooperatively activated TPO and Tg gene transcription and their 
synergistic activity require the cross-talk between enhancer and gene prompter.15 
Furthermore, Altmann et al. found that the transcriptional activation of hTg, hTPO and rNIS 
gene was low in cells expression either hPax-8 or dTTF-1 alone. In contrast, the activation of 
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hTg promoter and hTPO promoter and, to a lesser extend, of rNIS promoter were 
significantly activated in cell lines expression both TTF-1 and Pax-8.16 
To extend radioiodide therapy to undifferentiated thyroid carcinoma and other 
nonthyroid carcinoma, in the present study we constructed the adenovirus vectors (AdTTF-1 
and AdPax-8) for TTF-1 and Pax-8 gene transfer to induce reactivation of endogenous 
thyroid-specific genes. The ability of TTF-1 and Pax-8 to induce re-expression of 
thyroid-specific genes, NIS, Tg, and TPO, was investigated in human thyroid carcinoma 
cells and, then, radioiodine uptake and retention reactivated by TTF-1 and Pax-8 was 
examined in vitro or in vivo. The results reported here indicated that combining transfer of 
TTF-1 and Pax-8 gene was an available strategy to promote radioiodine therapy of 
non-iodide-concentration tumor. 
 
Materials and methods 
 
Cell culture 
K1 and F133 cells were purchased from European Collection of Animal Cell Cultures 
(ECACC, Wiltshire, UK) and HEK293 cells were kindly provided by Pathology Laboratory 
of West China Hospital, Sichuan University. The human papillary thyroid carcinoma cell 
line K1 has very low iodide uptake and NIS mRNA and protein in it is hardly detectable.17 
The human follicular thyroid carcinoma cell line F133 expresses Tg, and TSHR, but not 
TPO. The cell line does not take up iodide and hNIS mRNA expression in it is hardly 
detectable, too.18 All cell lines were grown in DMEM medium, high glucose content (Gibco, 
Carlsbad, CA, USA) with 10% fetal bovine serum, 2mmol/L L-glutamine, 100 IU/ml 
penicillin G and 100 μg/ml streptomycin sulfate. Cells were maintained at 37°C and 5% CO2 
in an incubator with 95% humidity. The culture medium was replaced every second day and 
cells were passaged at 90% confluency using 0.05% trypsin (Life Technologies). 
 
Recombinant adenovirus 
The full-length human TTF-1 cDNA (nucleotides 83~1288bp, GeneBank Acession 
Number: NM_001079668) and the full-length human Pax-8 cDNA (nucleotides 167~1519bp, 
GeneBank Acession Number: NM_003466) were respectively removed from the pMD-18T 
simple vector (reconstructed by Invitrogen Life Techonlogies) by restriction digestion using 
KpnI and HindIII, agarose gel purified and ligated into pShuttle plasmid (pAdTrack-CMV) 
of the AdEasier adenovirus system resulting in pAdTrack-TTF-1 and pAdTrack-Pax-8. 
Subsequently, homologous recombination of pAdTrack-TTF-1/pAdTrack-Pax-8 plasmid and 
pAdEasy-1 plasmid were performed in the bacteria BJ5183 Escherichia coli. The 
recombined adenovirus pAdTTF-1 and pAdPax-8 plasmid were agarose-gel purified and 
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confirmed by PCR and DNA sequencing. The pAdTTF-1 and pAdPax-8 were digested by 4 
mg PacI and, then they were packaged using Lipofectamine2000 (Invitrogen, Carlsbad, CA, 
USA) and respectively transfected into HEK293 cells according to the standard procedure. 
AdTTF-1 and AdPax-8 virus propagated in HEK293 cells. After two-step purification on 
CsCl gradients, viral stocks were desalted using Pharmacia G50 columns (Orsay, France) 
and frozen at 80℃ in 10 mM Tris-HCl (pH 7.5) containing 2.5% glycerol. Viral titers were 
determined by plaque assays using cultured HEK293 cells and were expressed as PFU/ml. 
 
Analysis of mRNA by RT-PCR 
Total RNA was prepared from cell lines using Trizol (Invitrogen) and quantitated 
spectrophotometrically. RT-PCR was performed using 2 μg of total RNA. The initial reverse 
transcription was at 42℃ for 1 h in 20 μl solution containing M-MLV Reverse Transcriptase 
100 U (Toyobo Co. Ltd., Osaka, Japan), 4 μl 5×first brand buffer, 0.1 mM oligo 
(deoxythymidine) 18 primer, 2 μl dNTPs mix (10 mM of each), 1 μl DTT (0.1 μl) and 6.0 μl 
ddH2O. cDNA aliquots equivalent to 100 ng RNA were subjected to PCR using Taq DNA 
polymerase (BioRule Biology Techonlogies, Shanghai, China). The primers and conditions 
used and the expected sizes of the target genes were shown in Table 1. For target genes 
amplification, cycling conditions were 5 min at 95℃ for pre-denaturation, 30 cycles of 45 s 
at 94℃ for denaturation, 30 s at various temperatures, as shown in Table 1 for annealing, 90 
s at 72℃ for extension followed by 10 min at 72℃ for final extension. PCR products (25μl) 
from each reaction were analyzed by 1.8 agarose/ethidium bromide gel electrophoresis. All 
amplification reactions were performed in triplicate and the relative expression levels were 
calculated as the density of the product of the respective target genes divided by that of the 
control gene, β-actin. 
 
Western blot analysis 
Total proteins (50 μg) prepared from transfected F133 cells were denaturated by water 
bath with 2×SDS gel loading buffer (Tris-HCl (pH 6.8) 100 mM, 4% SDS, 0.2% 
bromchlorphenol blue, 20% glycerine, 200 mM DTT) for 10 min at 100 ℃ and loaded on 
Bis-Tris-HCl buffered polyacrylamide gels. After bromchlorphenol blue run away from gel, 
proteins were transferred onto nitrocellulose membranes by electroblotting. Following 
blotting, membranes were preincubated for 2 h at room temperature in milk/TBS-T (20 mM 
Tris, 137 mM NaCl and 0.1% Tween-20, 5% non fat dry milk) to block nonspecific binding 
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sites. Membranes were then incubated with mouse monoclonal antibody against human 
NIS(Chemico Chemicals, New Delhi, India, dilution 1:500), mouse monoclonal antibody 
against human Tg (HuaAn Biotechnology, Hangzhou, China, dilution 1:200), or rabbit 
monoclonal antibody against human TPO (Bioss Company, Beijing, China, dilution 1:500) 
for 2 h at room temperature and then overnight at 4 ℃. After washing with TBS-T, 
horseradish peroxidase-labelled goat-anti-mouse-antibody was applied (dilution 1:2000) for 
1.5 h at 37 ℃. Membranes were washed with TBS-T and were exposed to X-ray films 
(Kodak Biomax MR, Sigma-Aldrich, St Louis, MO, USA) at room temperature for 
approximately 30s. Prestained protein molecular weight standards (Life Technologies) run in 
the same gels for comparison of molecular weight and estimation of transfer efficiency. 
 
Iodide uptake and efflux assay 
K1 and F133 Cells were plated into 6-well plates the day before infection at a seeding 
density of 1.0×106 cells per well, to reach 50%~70% confluence for infection. Cells were 
washed twice with PBS and incubated in serum-free medium. The virus at MOI (appropriate 
multiplicity of infection) in 1 ml serum-free medium were added to each well for 2 h, and 
then the serum-free medium were changed into complete medium. After infection for 48 h, 
cells were washed twice with PBS and incubated in 1 ml serum-free DMEM containing 
3.7KBq 125I, with or without 300 μM NaClO4. Following incubation at 37℃ for 5~120 min, 
the medium containing 125I were removed and the cells were washed twice with PBS. The 
cell-associated radioactivity at different time point was measured with a γ-counter. 
Iodide efflux studies were performed after K1 and F133 cells were infected with 
adenoviral as described above. Cells in per well were washed twice with PBS and incubated 
in 1 ml serum-free DMEM containing 3.7KBq 125I at 37℃ for 1 h. Cells were washed twice 
with PBS, and then 1 ml serum-free DMEM without radioactivity was added per well. The 
serum-free DMEM was replaced every 5 min for 30 min and the radioactivity of 125I in the 
collected medium was measured with a γ-counter. After the last time point, trapped 125I were 
removed from cells and were measured with a γ-counter. Total radioactivity at the beginning 
of the efflux study (100%) were calculated by summing radioactivity of collected medium at 
different time point and final radioactivity of cells. 
 
Radioiodine organification assay in vitro 
K1 and F133 cells were infected with adenovirus for 24 h as previously described. 
Methimazole (MMI, 500 μM), a TPO-specific inhibitor that acts by uncoupling 
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TPO-catalyzed oxidative iodination, was added in medium. After incubation in 
MMI-containing medium for 24 h, cells were then incubated in 1 ml DMEM (without serum) 
containing 3.7KBq 125I at 37 ℃ for 1 h. Medium containing 125I was removed, and cells were 
washed twice with PBS. Proteins in the cell lysates were precipitated by the addition of 0.5 
ml 40% trichloroacetic acid (TCA; final concentration, 20%). Precipitated proteins were 
collected by centrifugation at 3300 ×g for 30 min and were washed twice with PBS. 
Radioactivity in the pellets was measured with a γ-counter. 
 
Clonogenic assay in vitro 
K1 and F133 cells were infected with adenovirus for 48 h as previously described. Cells 
were washed twice with PBS and incubated with 37KBq 131I in serum-free medium. 
Following incubation with radioiodine for 7 h, cells were washed twice with PBS, 
trypsinized and plated in six-well plates (103/well). After 1~2 weeks, cell colony 
development, cells were fixed with methanol and stained with crystal violet (250 ml 
containing 0.5g crystal violet, 25 ml 40% formaldehyde, 50 ml ethanol, and 175 ml H2O), 
and colonies containing more than 50 cells were counted. The percentage of survival 
represents the percentage of cell colonies after 131I treatment, compared with no 131I 
intervention. 
 
Biodistribution of Na125I in vivo  
The experiments involving animals were performed in compliance with the current 
version of the national law on the Protection of Animals. One million F133 cells were 
subcutaneously injected into either thighs of 6-wk-old BALB/c nude mice. When tumors 
reached approximately 1cm in diameter by 2~3 wk after injection, AdTTF-1, AdTTF-1 and 
AdPax-8, or AdCMV (1.0×109 PFU in 100 μl PBS) were injected into the tumors for 3 days. 
Na125I (7.4×104 KBq) were injected via tail vein. The mice were sacrificed at 1, 2, 4, 8 and 
12 h after 125I injection. Tumor, blood, and selected tissues (heart, lung, spleen, liver, kidney, 
muscle, brain, bone, skin, stomach, intestine, thyroid gland) of the mice were dissected, 
blotted dry, weighted, and measured by γ-counting. Results are expressed as the percentage 
of injected dose per gram (%ID/g) of tissue. Each experiments were performed in triplicate. 
 
Tumor imaging 
Adenovirus were injected into the tumor on the thigh of nude mice as previously 
described. The tumor-bearing mice were injected with 18.5 MBq of Na131I via tail vein. The 
tumor-bearing mice were imaged with a γ-camera equipped with a low-energy, 
high-resolution pinholes collimator (Philips Medical Syst., Milpitas, CA, USA) at 2, 4, 8, 12 
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and 24 h after Na131I injection. Per image was acquired with 256×256 matrix, 2 times 
magnify, at least 100K total counts. 
 
Statistical analysis 
All experiments were carried out in triplicates or more under the same conditions. 
Results are presented as means±SD. Statistical significance was tested using Student’s t-test. 
P<0.05 was considered statistically significant.  
 
Results 
 
Expression of NIS, Tg and TPO mRNA induced by AdTTF-1 and AdPax-8 
To investigate the effect of TTF-1 and Pax-8 on the expression of NIS, Tg and TPO 
mRNA, F133 cells were infected with 50 MOI AdTTF-1, 20 MOI AdPax-8 and 30 MOI 
AdTTF, or 20 MOI AdCMV (control adenovirus). After 2h of infection with adenoviral 
vectors, cells were incubated in adenovirus-free medium for 48 h. Based on RT-PCR 
analysis, AdTTF-1 alone could promote the expression of NIS mRNA in F133 cells and it 
had little effect on the expression of Tg and TPO mRNA. Comparatively, not only the 
expression of NIS mRNA but also Tg and TPO mRNA in F133 cell were activated in F133 
cells coinfected with AdTTF-1 and AdPax-8 (Fig. 1). These findings indicate that TTF-1 
specifically promoted the expression of NIS mRNA and, TTF-1 and Pax-8 could 
synergistically reactive all of the expression of NIS, Tg and TPO mRNA in F133 cells.  
 
AdTTF-1 and AdPax-8 induced expression of Tg and TPO proteins 
   To analyze whether NIS, Tg and TPO mRNA reactivated by TTF-1 and Pax-8 are 
translated into proteins, NIS, Tg and TPO proteins in F133 cells coinfected with AdTTF-1 
and AdPax-8  were determined by Western blot analysis. Forty-eight hours after infection 
with adenoviral vectors as previously described, total proteins in F133 cells were abstracted 
to Western blot analysis (Fig. 2). In AdTTF-1-infected F133 cells, NIS proteins were 
increased, but Tg and TPO proteins were very low and hardly detectable. In contrast, all of 
the expression of NIS, Tg and TPO proteins were increased in AdTTF-1 and AdPax-8 
coinfected F133 cell (Fig. 2). These results clearly showed that NIS mRNA promoted by 
TTF-1 and, NIS, Tg and TPO mRNA promoted by TTF-1 and Pax-8 in F133 cells are all 
translated into proteins. 
 
AdTTF-1 and AdPax-8 induced iodide uptake 
Because TTF-1 and Pax-8 could synergistically promote NIS expression in F133 cells, 
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we speculated that radioiodine uptake increased in cells infected with AdTTF-1 and AdPax-8. 
To analyze the function of NIS protein induced by TTF-1 and Pax-8, we measured the 
radioiodine uptake in K1 and F133 cells infected with AdTTF-1 and AdPax-8. K1 and F133 
cells were infected with adenoviral vectors as previously described. Iodide uptake studies 
were performed after incubating the cells in serum-free DMEM containing 3.7KBq 125I. 
Radioiodine uptake in AdCMV-infected K1 and F133 cells were faint and showed little 
change even after 2 h incubation with 125I. Comparatively, radioiodine uptake in 
AdTTF-1-infected or AdTTF-1 and AdPax-8-coinfected K1 and F133 cells were rapidly 
increased and reached maximum at 30 min, thereafter, they gradually decreased as time 
passing. (Fig. 3). 
AdTTF-1 and AdPax-8 coinfected K1 and F133 cells showed a relative higher 
radioiodine uptake than that in K1 and F133 cells infected with AdTTF-1 alone. At 30 min 
after incubation with 125I, radioiodine uptake in K1 and F133 cells infected with AdTTF-1 
was respectively 10597±648 cpm (cells per well) and 12445±513 cpm, and it increased 
about 6.1-fold and 7.4-fold over that in AdCMV-infected K1 and F133 cells, respectively 
(P<0.05). Meanwhile, at 30 min after incubation with 125I, radioiodine uptake in AdTTF-1 
and AdPax-8-coinfected K1 (13103±1503 cpm) and F133 cells (14398±237 cpm) increased 
about 6.6-fold and 7.5-fold over that of AdCMV-infected K1 and F133 cells, respectively 
(P<0.05) (Fig. 3). The iodide accumulation in K1 and F133 cells induced by AdTTF-1 and 
AdPax-8 were almost completely inhibited by sodium perchlorate. These results suggest that 
TTF-1 and Pax-8 could synergistically promote radioiodine uptake in thyroid carcinoma 
cells by inducing the expression of NIS protein.  
 
AdTTF-1 and AdPax-8-induced radioiodine organification 
Because AdTTF-1 and AdPax-8 could induce the expression of Tg and TPO proteins 
(Fig. 2) in F133 cells, We try to further investigate whether iodide in K1 and F133 cell 
infected with AdTTF-1 and AdPax-8 would organized by the catalysis of TPO. We 
pretreated AdTTF-1 and AdPax-8 infected K1 and F133 cells with the TPO inhibitor MMI, 
and then exposed cells to 125I. As predicted, AdTTF-1-infected K1 and F133 cells showed no 
apparent increase in intracellular protein-bound radioiodine. In contrast, AdTTF-1 and 
AdPax-8 significantly enhanced radioiodine organification in K1 and F133 cells. The 
protein-bound radioiodine in AdTTF-1 and AdPax-8 coinfected K1 cells was 11576±857 
cpm, and it was about 13.1-fold and 4.3-fold higher than that of AdCMV-infected K1 cells 
(820±175 cpm, P<0.01) and AdTTF-1-infected K1 cells (2170±648 cpm, P<0.01), 
respectively. Meanwhile, the protein-bound radioiodine in AdTTF-1 and AdPax-8 coinfected 
F133 cells coinfected was 11995±865 cpm, and it was about 11.1-fold and 5.3-fold higher 
than that of AdCMV-infected F133 cells (990±181 cpm, P<0.01) and AdTTF-1-infected 
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F133 cells (1893±535 cpm, P<0.01), respectively. The protein-bound radioiodine induced by 
AdTTF-1 and AdPax-8 were very sensitive to MMI pretreatment and it were almost 
completely inhibited by MMI (p<0.01). These results demonstrated that TPO induced by 
AdTTF-1 and AdPax-8 catalyzed iodide organification in K1 and F133 cells (Fig. 4). 
. 
AdTTF-1 and AdPax-8 induced the prolongation of iodide efflux 
We have demonstrated that AdTTF-1 and AdPax-8 could promote iodide uptake (Fig. 
3) and induce iodide organification (Fig. 4) in K1 and F133 cells. To determine whether 
TTF-1 and Pax-8 cotransfer could prolong radioiodine retention in K1 and F133 cells, we 
performed a radioiodine efflux assay. AdTTF-1 and AdPax-8 infected K1 and F133 cells 
were exposed to radioiodine, and the release of radioactivity into the medium was monitored 
every 5 min. There was a rapid efflux of radioactivity from K1 and F133 cells infected with 
either AdTTF-1(t1/2≈8 min) or AdCMV (t1/2≈6 min), and cellular radioactivity was almost 
completely released into the medium over 30 min. In contrast, iodide efflux was prolonged 
in AdTTF-1 and AdPax-8 coinfected K1 and F133 cells (t1/2≈25 min and 30 min, 
respectively) (Fig. 5). These results indicate that TTF-1 and Pax-8 cotransfer could 
effectively inhibit iodide efflux and prolong radioiodine retention in K1 and F133 cells. 
 
Clonogenic assay in vitro 
We want to know therapeutic effect of radioiodine on K1 and F133 cells cotransfected 
with AdTTF-1 and AdPax-8 because AdTTF-1 and AdPax-8 induced iodide uptake and 
prolonged iodide retention in K1 and F133 cells (Fig 3 and Fig 5). After 131I treatment, 
clonogenic assay were performed and results are shown in Figure 6. Following exposure to 
131I, about 20% of AdCMV-infected K1 or F133 cells were nonselectively killed. After 131I 
treatment, the  survival rate of AdTTF-1-infected K1 and F133 cells were 40% and 43%, 
respectively, and that of AdTTF-1 and AdPax-8 coinfected K1 and F133 cells were 21% and 
25%, respectively, which were apparently lower than that of AdCMV-infected K1 or F133 
cells (p<0.05). Moreover, the survival rate of K1 and F133 cells coinfected with AdTTF-1 
and AdPax-8 were obviously lower than that of K1 and F133 cells infected with AdTTF-1 
(p<0.05). These data demonstrate that coinfection with AdTTF-1 and AdPax-8 obviously 
enhanced the effect of radioiodine therapy of K1 and F133 cells. 
 
TTF-1 and Pax-8 induce iodide accumulation in vivo 
We demonstrated that AdTTF-1 and AdPax-8 could promote radioiodine 
accumulation and prolong radioiodine retention in K1 and F133 tumor cells in vitro. In order 
to extend those results to an in vivo model, biodistribution of 125I was performed on 
F133-bearing mice. The quantitation of the 125I uptake (%ID/g) in the tumors and other 
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tissues was evaluated at 1, 2, 4, 8 and 12 h after 125I administration. The biodistribution data 
of radioiodine in F133-bearing mice after intratumoral injection of AdTTF-1, AdTTF-1 and 
AdPax-8, were summarized in Figure 7. The AdCMV-infected F133 tumor accumulated a 
lower amount of the radioiodine than did AdTTF-1-infected F133 tumor or AdTTF-1 and 
AdPax-8 coinfected F133 tumor. The radioactivity in AdCMV-infected tumor was faintly 
increased, thereafter, it gradually decreased. The 125I uptake in TTF-1-expressing F133 
tumor quickly increased in 2 h after 125I administration. The 125I concentration in 
TTF-1-expressing tumor was 7.61±1.17 %ID/g and 4.24±1.44 %ID/g at 2 and 4 h after 125I 
administration, respectively. After that, 125I concentration in it rapid decreased. At 12h after 
125I administration, only 0.14±0.04 %ID/g radioiodine remained in it. In contrast, the 125I 
concentration in AdTTF-1 and AdPax-8 coinfected F133 tumor rapidly increased in 1 h, 
after that, it gradually decreased. The 125I concentration in F133 tumor coinfected with 
AdTTF-1 and AdPax-8 tumor was 9.42±0.83 %ID/g and 8.32±1.14 %ID/g at 2 h and 4 h 
after 125I administration, respectively. At 12h after 125I administration, 5.64±0.67 %ID/g 
radioiodine still remained in it, which were obviously higher than that in AdTTF-1-infected 
tumor (P<0.05). The average biological half-life of radioiodine in F133 tumor infected with 
AdCMV, AdTTF-1, AdTTF-1 and AdPax-8 was 3.75 h, 4.7 h and up to 12 h, respectively.  
All of other organs accumulated slight radioiodine, no more than 5.8 %ID/g (intestine) 
at all time, except thyroid and stomach. The tumor/blood and tumor/muscle 125I uptake ratios 
of AdTTF-1-infected F133 tumor were 1.81±0.46 and 3.59±0.87 at 8 h after 125I 
administration, respectively, which were higher than that of AdCMV-infected F133 tumor 
(0.68±0.16 and 1.34±0.41, respectively) (P<0.05). Comparatively, the tumor/blood and 
tumor/muscle 125I uptake ratios of F133 tumor coinfected with AdTTF-1 and AdPax-8 were 
3.42±0.51 and 11.09±1.14 at 8 h after 125I administration, respectively, which were higher 
than that of AdTTF-1- or AdCMV-infected F133 tumor (P<0.05). These data demonstrate 
that AdTTF-1 and AdPax-8 promoted radioiodine accumulation and prolonged radioiodine 
retention in F133 tumor in vivo. 
 
Tumor Imaging 
Radioiodine uptake in tumor was determined using a γ camera at 2, 4, 8, 12 and 24 h 
after 131I injection (Fig. 8). AdTTF-1-infected F133 tumors accumulated 131I rapidly and 
were early visualized at 2 h after 131I administration. However, they quickly attenuated after 
4h and were hardly visible at 12 h. In contrast, the F133 tumors coinfected with AdTTF-1 
and AdPax-8 began to show at 2 h and they were still visualized at 24h after 131I 
administration. Some normal organs expressing NIS (including those of thyroid, stomach) 
and involved in iodide elimination (bladder) showed clearly. 
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Discussion 
 
Distant metastasis is the first primary cause of death to most patients with cancer, 
because no durative therapy for metastases. In contrast, DTC, even with distant metastases, 
can be effectively treated by radioiodine because of the unique ability of carcinoma cells to 
concentrate iodine from plasma. The special property of DTC makes it to be one of the most 
manageable cancers.19 It was postulated that reexpression of iodide-metabolic relative 
proteins would restore/acquire iodine uptake in cancer and enable them be treated by 
radioiodine. Mandell et al. initially proposed NIS-based radioiodine concertrator gene 
therapy for extrathyroidal cancer.20 It has shown that the transfer of NIS gene confers 
increased radioiodine uptake in thyroid cancer21, breast cancer22, hepatoma23 and prostate 
cancer24, et al. These studies demonstrated that NIS-transducted tumor cells could 
significantly accumulated radioiodine, and consequently, be selectively killed by radioiodine 
in vivo and in vitro.20, 24~26 However, rapid radioiodine efflux form NIS-transfected cells 
may impact the antitumor efficacy of this therapeutic strategy.  
All of the expression of iodide-metabolic relative proteins such as NIS, Tg and TPO in 
thyroid are regulated by TTF-1 and/or Pax-8. Maybe it is a possible strategy to 
simultaneously stimulate the expression of NIS, Tg and TPO in tumor cells and, to promote 
radioiodine uptake and prolong iodide retention in tumor cells at one time, by transfer TTF-1 
and/or Pax-8 gene. Our group has found that Pax-8 could activate the expression of TPO and 
Tg proteins in human thyroid carcinoma cells. The radioiodine uptake was partially restored 
and T½ of 131I in thyroid carcinoma cells was apparently prolonged by Pax-8 (data in 
manuscript). In the present report, we further co-transferred TTF-1 and Pax-8 gene by 
adenovires vectors and discovered that TTF-1 alone could specially induced the expression 
of NIS and the synergetic effect of TTF-1 and Pax-8 could simultaneously induce the 
reexpression of NIS, TPO and Tg proteins in human thyroid carcinoma F133 cells. TTF-1 
and Pax-8 cotransducted K1 and F133 cells could accumulated more radioiodine and 
obviously retarded radioiodine efflux than TTF-1-transfected K1 and F133 cells in vitro and 
in vivo. Consequently, the effect of radioiodine therapy of TTF-1 and Pax-8 cotransfected 
K1 and F133 cells was better than that of TTF-1 transfected cells. 
In this study, we discovered that AdTTF-1 specially activated the expression of NIS in 
F133 cells, and which were further promoted in TTF-1 and Pax-8 cotransfected F133 cells. 
Accordingly, the radioiodine uptake was obviously increased in both AdTTF-1-infected and 
AdTTF-1 and AdPax-8 coinfected K1 and F133 cells. Altmann et al. found that TTF-1 has 
no induction or a low induction of transcriptional activation of NIS promoter. On the other 
hand, the activation of rNIS promoter (up to 6-fold) were activated in cell lines expression 
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both TTF-1 and Pax-8.16 However, Furuya et al. found that no detectable NIS expression 
was show in thyroid carcinoma (BHP18-21v) cells, regardless of whether they infected with 
AdTTF-1. But AdTTF-1 induced a small, but significant, iodide accumulation, that was 
inhibited by sodium perchlorate in BHP18-21v cells.27 Schmitt et al. also reported that 
TTF-1 had no influence in the activation of NIS promoter and Pax-8 had a moderate 
stimulating effect (3 folds) on the NIS promoter in Hela and COS-7 cells.28 To explain this 
observations, it could be speculated that the expression of NIS activated by TTF-1 had the 
cell-specificity because Endo T et al. observed that TTF-1 can bind to a minima 5’-flanking 
sequence region (between -291 and -134 bp) of NIS gene extracts from a rat thyroid cell line, 
FRTL-5 cells, but not BRL-3A rat liver cells, forming a specific DNA-protein complex and 
causing a significant increase in the transcriptional activity of the promoter of rat NIS gene.8 
Moreover, the study that TTF-1 is a phosphoprotein and phosphorylation is reduced in the 
Ha-ras traformed thyroid cells, where TTF-1 is unable to activate transcription from the Tg 
promoter, suggests a possible mechanisms whereby differential phosphorylation of TTF-1 in 
different cell types could be responsible for its promoter selection.29  
The therapeutic efficacy of radioiodine is dependent on the radiation dose delivered to 
the target tissue and, the radiation dose delivered to a tumor is dependent on two factors: the 
radioactive concentration of 131I and the effective half-life (T½) of 131I in the tumor. T½ of 131I 
in thyroid carcinoma, which had response to 131I therapy, was 78.8 h. The effect of 131I 
therapy was not satisfactory if T½ of 131I was shorter than 45.8 h.30 Rapid radioiodine efflux 
after sufficient iodide uptake is probably the main problem of NIS-transduction. Although 
the tumors efficiently concentrated iodide after NIS gene transfer, no effect of 131I on tumor 
growth was observed because the rapid iodide efflux from the tumor did not allow the 
delivery of a radiation dose sufficient to inhibit cell growth.21, 31, 32 Thus, to efficiently 
therapy tumor with 131I by gene transfer, it is mandatory to increase the retention time of 
iodide in the tumor. An appealing strategy is to mimic the situation existing in the thyroid, 
i.e., to organify the iodide taken up by the tumor. TPO is the main enzyme to catalysis iodide 
organification in thyroid. Any iodide not organified by TPO will rapidly efflux from thyroid 
follicular cells.33 Some researchers try to inhibit iodide efflux by reexpressing TPO in tumor 
cell. Haberkorn et al. found that the accumulation of iodide was not significantly enhanced 
and there was no correlation between hTPO expression and enzyme activity in human 
anaplastic thyroid carcinoma cells transfered human TPO gene. They presumed that the 
transduction of hTPO gene was not sufficient to restore iodide trapping in 
non-iodide-concentration tumor cells.34 After that, Huang et al. transfected non-small cell 
lung cancer cells with human NIS and TPO genes. They discovered that the combination of 
NIS and TPO gene transfection, with resulting in NIS-mediated iodide uptake and 
TPO-mediated organification and intracellular retention of radioiodine, might lead to more 
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effective radioiodine therapy of tumor.35 However, Bland et al. reported that an increasing of 
iodide organification could be observed in rat thyroid FRTL-5 cells coinfected with both 
AdNIS and AdTPO in the presence of exogenous hydrogen peroxide, but the levels of iodide 
organification obtained were too low to significantly increase the iodide retention time in the 
target cells.36 In the current study, the expression of Tg and TPO in F133 cell, not like that of 
NIS, was not promoted by Ad-TTF-1. Besides, while combining with Pax-8, the activating 
effect of TTF-1 on the expression of Tg and TPO was apparently enhanced. The results of 
radioiodine organification assay and radioiodine efflux analysis demontrated that, following 
with the expression of Tg and TPO, radioiodine organized and radioiodine retention time 
obviously prolonged in Ad-TTF-1 and Ad-Pax-8 coinfected F133 cells, comparing with that 
in Ad-F133 or Ad-CMV infected F133 cells. Altmann et al. also reported that TTF-1 could 
not activate Tg and TPO promoter, but the activation of hTg promoter (up to 23-fold) and 
hTPO promoter (up to 28-fold) were significantly activated in cell lines expression both 
TTF-1 and Pax-8.16 These results indicated efficient iodide organification and retention 
induced by TTF-1 and Pax-8. 
We hope that the efficacy of radioiodine therapy for TTF-1 and Pax-8 cotransfected 
tumor would improved because the sufficient iodide accumulation and retarded iodide 
retention were observed in TTF-1 and Pax-8 cotransfected K1 and F133 cells. The data from 
biodistribution of radioiodine in vivo showed that TTF-1 and Pax-8 cotransducted cancer 
could accumulate significantly more radioiodine than parental tissue, and comparatively, 
Ad-TTF-1 and Ad-Pax-8 coinfected F133 and K1 cells were selectively and efficiently killed 
by radioiodine in vitro. The effective half time of radioiodine in F133 tumor infected 
Ad-TTF-1 and Ad-Pax-8 was about 12 h, which was obviously shorter than the mean 
effective half time of radioiodine in DTC (78.8h).37 We speculated it was due to the defect of 
transfer gene technology itself, because it is unlikely to achieve 100% transfection rate in 
vivo. The powerful gene delivery systerms toward clinical application must be performed in 
further studies. Besides, the combinatorial strategy should be considered to improve the 
efficacy of radioiodine therapy for tumor following gene transfer.  
Another approach involved the use of more powerful and suitable radionuclides transported by 
NIS, such as 188Re-perrhenate or 211At rather than 131I. 188Re-Perrhenate is a β-emitter and has a 
shorter half life (T1/2) and is effective over a wider range than 131I.38, 39 188Re-perrhenate has been 
proposed to use in the treatment of NIS expressing tumors as an alternative to 131I because 
188Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor, and dosimetry 
calculations in the mammary tumor demonstrate that 188Re-perrhenate was able to deliver a dose 4.5 
times higher than 131I.38 Moreover, in NIS-transfected prostate cancer, tumor absorbed dose for 188Re 
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was 4.7-fold compared with 131I and therapeutic effect of 188Re in larger tumors was superior to that 
of 131I.37 Besides, 211At is regard as a promising radionuclide for cell-targeted radiotherapy owing to a 
combination of favourable properties, including short half-life (7.2 h) and decay via a bibranch 
pathway emitting two α-particle types (6.8 MeV mean energy), leading to deposition of high energy 
over a short distance (55~88 μm mean tissue range). 211At uptake is shown to be NIS-dependent, with 
characteristics similar to 131I uptake.40 NIS-expressing tumor cells could effectively accumulate 211At 
and tumor absorbed dose for 211At was significantly higher than that for 131I (3.5 Gy/MBqtumour for 131I 
and 50.3 Gy/MBqtumour for 211At).41 In this study, radioiodine rapidly flowed into tumor cells infected 
AdTTF-1 and AdPax-8 after iodide administration. We speculate that 188Re and 211At might be used 
to therapy tumors expressing TTF-1 and Pax-8 with superior therapy effect compared as 131I, and 
which need be demonstrated by further studies. 
A better understanding of the mechanisms governing iodide transport in the cells may 
provide better solutions to efficiently improve iodide retention. Indeed, an increased iodide 
retention time could be obtained by specifically blocking the mechanism controlling iodide 
efflux. Pendrin is a glycoprotein protein located at the apical membrane of thyrocytes, which 
is thought to be involved in iodide efflux from the intracellular compartment to the follicular 
lumen in the thyroid gland.42 Other proteins (SLC5A8 and chloride channel 5 ClCn5) have 
been proposed to mediate apical iodide efflux.43,44 Functional studies performed in Xenopus 
oocytes and polarized Madin-Darby canine kidney (MDCK) cells clearly demonstrate that 
SLC5A8, originally designated as human apical iodide transporter (hAIT)43, does not 
mediate iodide uptake or efflux.45 Localization of the ClCn5 protein at the apical membrane 
of thyrocytes and a thyroidal phenotype of the ClCn5-deficient mice that is reminiscent of 
Pendred syndrome suggest that ClCn5 could be involved in mediating apical iodide efflux or 
iodide/chloride exchange.44 This possibility has, as of yet, not been demonstrated by further 
experimental data. 
In conclusion, TTF-1 can specially activate the expression of NIS, resulting in an 
increasing radioiodine accumulation in K1 and F133 cell. However, no detectable induction 
of Tg and TPO proteins expression is observed in TTF-1 tansducted F133 cell, following 
limited iodine organification and retention. Comparatively, the synergy of TTF-1 and Pax-8 
can simultaneously activate the expression of NIS, Tg and TPO proteins in F133 cells, and 
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induces more significant radioiodine accumulation and obviously radioiodine retention than 
TTF-1 alone. TTF-1 and Pax-8 cooperatively promote the therapeutic effect of radioiodine 
on thyroid carcinoma cells. The cotransduction of TTF-1 and Pax-8 gene is a feasible 
strategy to promote the effect of radioiodine therapy on non-iodide-concentrating tumor. 
Further studies will concentrate on enhancing the effect of radionuclide therapy conducted 
by TTF-1 and Pax-8 gene cotransfer through using more powerful therapeutic radionuclides, 
such as 211At and 188Re. 
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Table 1. Primer sequences, conditions, and product sizes for the RT-PCR 
Primer Primer Squences Annealing Temperature Product Sizes 
NIS-FP 5’-ctctctcagtcaacgcctctgg-3’ 
57℃ 316 bp 
NIS-RP 5’-cccttgaccaagttgtcatccag-3’ 
Tg-FP 5’-ggctaatgctacatgtcctg-3’ 
57℃ 231bp 
Tg-RP 5’-gcttctgttggagatgctgg-3 
TPO-FP 5’-gtctgtcaggctggttatgg-3’ 
57℃ 242bp 
TPO-RP 5’-caatcactccgcttgttggc-3’ 
β-actin-FP 5’-ctggcaccacaccttctacaatg-3’
56℃ 250bp β-actin-RP 5’-cctcgtagatgggcacagtgtg-3’ 
 
 
Fig 1. Expression of NIS, Tg and TPO mRNA in F133 cells induced by AdTTF-1 and AdPax-8. The mRNA levels of 
thyroid-specific genes in F133 cells infected with AdTTF-1 and AdPax-8 were investigated by RT-PCR analysis. 
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F133 cells were infected with AdTTF-1, AdTTF and AdPax-8, or AdCMV for 2h, then incubated with 
adenovirus-free medium for 48 h. Total mRNA (100ug) were subjected to RT-PCR using human NIS, Tg, TPO or 
β-actin primer. NIS, Tg and TPO mRNA levels were normalized with β-actin mRNA levels, based on optical density 
measurements and compared to β-actin (n=3). 
 
 
Fig 2. Expression of NIS, Tg and TPO proteins in F133 cells induced by AdTTF-1 and AdPax-8. The protein levels 
of NIS, Tg and TPO in F133 cells infected with AdTTF-1, AdTTF and AdPax-8, or AdCMV were investigated by 
Western-blot. F133 cells were infected with AdTTF-1, AdPax-8, AdTTF and AdPax-8, or AdCMV for 2h, then 
incubated with adenovirus-free medium for 48 h. Total proteins (50 μg) were subjected to Western Blot analysis as 
described in Methods. NIS, Tg and TPO protein was observed as the major band of molecular weight at 90 kDa, 660 
kDa and 87 kDa, respectively. Tg and TPO protein levels were normalized with β-actin protein levels, based on 
optical density measurements and compared to β-actin  (n=3). 
 
 
Fig 3. Time course of iodide uptake in K1 and F133 cells induced by AdTTF-1- and AdPax-8. K1 (A) and F133 (B) 
cells were infected with AdTTF-1, AdTTF and AdPax-8, or AdCMV for 2h, then incubated with adenovirus-free 
medium for 48 h. All cells were exposed to medium containing 3.7 KBq Na125I with or without 300 μM NaClO4. At 
various time points, the cells were washed twice and intracellular radioactivity was measured with a γ-counter. Data 
are expressed as the mean ± SEM (n=6). 
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Fig 4. Iodide organification in K1 and F133 cells induced by AdTTF-1 and AdPax-8. K1 and F133 cells were 
infected with AdCMV, AdTTF and AdPax-8 for 2 h, then incubated with adenovirus-free medium for 24 h. The 
medium containing 125I were replaced with medium with or without 500 μM MMI for 24 h. Cells were exposed to 3.7 
KBq Na125I for 1 h and then the radioactivity of 125I-bound protein in cells was determined by TCA precipitation. 
Data are expressed as the mean ± SEM (n = 6). *, P<0.01, compared with MMI-inhibited cells; △, P < 0.01, 
compared with AdCMV-infected cells. 
 
 
Fig 5. Iodine efflux from AdTTF-1- and AdPax-8 infected K1 and F133 cells. K1 (A) and F133 (B) cells were 
infected with AdTTF-1, AdTTF and AdPax-8, or AdCMV for 2h, then incubated with adenovirus-free medium for 
48 h. All cells were incubated in serum-free medium containing 3.7 KBq Na125I for 1 h. Cells were washed twice 
with PBS, and the medium was replaced with nonradioactive medium every 5 min. The radioactivity in the replaced 
medium was measured with a γ-counter. After the last medium was removed, the cells were extracted. The total 
radioactivity present at the initiation of the efflux study (100%) was calculated by adding the counts in the final cells 
to the medium counts at various time point. Data are expressed as the mean ± SEM (n=6). 
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Fig 6. The effect of 131I therapy of K1 and F133 tumors transfected with AdTTF-1 and AdPax-8 in vitro. In 
clonogenic assay in vitro, K1 or F133 cells were infected with dTTF-1, AdTTF and AdPax-8, or AdCMV and then 
exposed to 37 KBq Na131I for 7 h. Cells were washed with PBS and plated in six-well plates. After 2~3 weeks, cells 
were fixed with methanol and stained with crystal violet, and colonies containing more than 50 cells were counted. 
The percentage of survival represents the percentage of cell colonies after 131I therapy, compared with no 131I 
intervention. Data are expressed as the mean ± SEM (n=3). *, P< 0.05, compared with AdCMV-infected cells; △, P < 
0.05, compared with AdTTF-1-infected cells. 
Fig 7. Biodistribution of radioiodine in nude mice bearing F133 tumor cells. After AdTTF-1 and AdPax-8, or 
AdCMV (1.0×109 pfu) were injected into tumors for 3 d, 7.4×104Bq Na125I were injected via tail vein. The mice were 
sacrificed at 1, 2, 4, 8 and 12 h and various tissues (tumor, blood, heart, lung, liver, et al.) of the mice were dissected. 
The radioactivity of various tissues were measured with a γ-counter. Results are expressed as the percentage of 
injected dose per gram (%ID/g) of tissue (n=3). *, P<0.05, compared with blood; Δ, P<0.05, compared with muscle; 
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﹟P<0.05, compared with AdTTF-1-infected tumor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8. Whole-body scintigraphic images of nude mice transplanted with F133 cells infected with AdTTF-1 and 
AdPax-8. Tumor imaging studies were performed after AdTTF-1 (A), AdTTF-1 and AdPax-8 (B) were injected into 
tumors for 3 d. At 2, 4, 8, 12 and 24 h after Na131I (18.5 MBq /rat) were injected i.p., mice were imaged with a γ 
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camera. 
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 Table 1. Primer sequences, conditions, and product sizes for the RT-PCR 
Primer Primer Squences Annealing Temperature Product Sizes 
NIS-FP 5’-ctctctcagtcaacgcctctgg-3’ 
57℃ 316 bp 
NIS-RP 5’-cccttgaccaagttgtcatccag-3’ 
Tg-FP 5’-ggctaatgctacatgtcctg-3’ 
57℃ 231bp 
Tg-RP 5’-gcttctgttggagatgctgg-3 
TPO-FP 5’-gtctgtcaggctggttatgg-3’ 
57℃ 242bp 
TPO-RP 5’-caatcactccgcttgttggc-3’ 
β-actin-FP 5’-ctggcaccacaccttctacaatg-3’
56℃ 250bp β-actin-RP 5’-cctcgtagatgggcacagtgtg-3’ 
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